is glp 1 a specialty drug Addressing GLP-1 Access and Adherence Challenges with Pharmacy Solutions For users of GLP-1 drugs
Description
Anyone who gets pregnant while using them should speak to their healthcare professional and stop the medicine as soon as possible
Tirzepatide Once Weekly for the Treatment of Obesity | New England Journal of Medicine Note: the FDA considers body composition metrics to be safety endpoints which often results in underpowered secondary endpoints in Phase 3 registration trials
Patients with DT2 without obesity or excess weight with comorbidities can use liraglutide 1.8mg (daily, subcutaneous) and semaglutide 1mg (weekly, subcutaneous), or 14mg (daily, oral) for glycemic control
The beneficial effect of tirzepatide on UACR was confirmed by a post-hoc analysis of SURPASS-1 (vs
